Login to Your Account

Myogen Riding High After Preliminary PAH Findings

By Aaron Lorenzo

Tuesday, December 13, 2005
Positive Phase III news sent Myogen Inc.'s stock soaring 40.5 percent, with top-line data demonstrating ambrisentan's ability to improve symptoms of pulmonary arterial hypertension. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription